STAG2 and chronic myelogenous leukemia, BCR-ABL1 positive: We had previously shown that BET inhibition is effective in blocking precocious gene expression in the chronic myelogenous leukemia cell line K562 containing a STAG2 mutation (Antony et al., 2020).